OXALIPLATIN PLUS CAPECITABINE (XELOX) AS FIRST-LINE CHEMOTHERAPY FOR ELDERLY PATIENTS WITH ADVANCED GASTRIC CANCER: RESULTS OF A MONOCENTRIC EXPERIENCE

被引:0
|
作者
Rozzi, A. [1 ]
Corona, M. [1 ]
Nardoni, C. [1 ]
Restuccia, M. [2 ]
Lanzetta, G. [1 ]
机构
[1] Clin Oncol Unit INI Grottaferrata, Grottaferrata, Italy
[2] Univ Roma La Sapienza, Dept Med Oncol, Rome, Italy
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:90 / 90
页数:1
相关论文
共 50 条
  • [1] Triweekly Oxaliplatin Plus Oral Capecitabine as First-Line Chemotherapy in Elderly Patients With Advanced Gastric Cancer
    Dong, Ningning
    Jiang, Wanrong
    Li, Huiqing
    Liu, Zhifang
    Xu, Xiaoqing
    Wang, Mingyu
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2009, 32 (06): : 559 - 563
  • [2] A Phase II Study of Capecitabine plus Oxaliplatin as First-Line Chemotherapy in Elderly Patients with Advanced Gastric Cancer
    Xiang, Xiao Jun
    Zhang, Ling
    Qiu, Feng
    Yu, Feng
    Zhan, Zheng Yu
    Feng, Miao
    Yan, Jun
    Zhao, Jian Guo
    Xiong, Jian Ping
    [J]. CHEMOTHERAPY, 2012, 58 (01) : 1 - 7
  • [3] First-line capecitabine (X) monotherapy versus capecitabine plus oxaliplatin (XELOX) in elderly patients with advanced gastric cancer (AGC): results from the first interim analysis.
    Hwang, In Gyu
    Lee, Hyo Rak
    Lee, Hui Young
    Ji, Jun Ho
    Kang, Jung Hun
    Lee, Soon Il
    Kim, Seung Tae
    Lee, Jeeyun
    Park, Se Hoon
    Kang, Won Ki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer
    Yeon Hee Park
    Jae-Lyun Lee
    Baek-Yeol Ryoo
    Min-Hee Ryu
    Sung Hyun Yang
    Bong Seog Kim
    Dong Bok Shin
    Heung Moon Chang
    Tae Won Kim
    Young Jin Yuh
    Yoon-Koo Kang
    [J]. Cancer Chemotherapy and Pharmacology, 2008, 61 : 623 - 629
  • [5] Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer
    Park, Yeon Hee
    Lee, Jae-Lyun
    Ryoo, Baek-Yeol
    Ryu, Min-Hee
    Yang, Sung Hyun
    Kim, Bong Seog
    Shin, Dong Bok
    Chang, Heung Moon
    Kim, Tae Won
    Yuh, Young Jin
    Kang, Yoon-Koo
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (04) : 623 - 629
  • [6] A phase II study of capecitabine plus oxaliplatin (XELOX) as first-line therapy for patients with advanced gastric cancer.
    Park, Y.
    Lee, J.
    Ryoo, B.
    Ryu, M.
    Yang, S.
    Kim, B.
    Shin, D.
    Chang, H.
    Kim, T.
    Kang, Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 197S - 197S
  • [7] XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer
    Feliu, J
    Salud, A
    Escudero, P
    Lopez-Gómez, L
    Bolaños, M
    Galán, A
    Vicent, JM
    Yubero, A
    Losa, F
    De Castro, J
    de Mon, MA
    Casado, E
    González-Barón, M
    Oncopaz Cooperative Grp
    [J]. BRITISH JOURNAL OF CANCER, 2006, 94 (07) : 969 - 975
  • [8] XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer
    J Feliu
    A Salud
    P Escudero
    L Lopez-Gómez
    M Bolaños
    A Galán
    J-M Vicent
    A Yubero
    F Losa
    J De Castro
    M Á de Mon
    E Casado
    M González-Barón
    [J]. British Journal of Cancer, 2006, 94 : 969 - 975
  • [9] Phase II trial of oxaliplatin plus oral capecitabine as first-line chemotherapy for patients with advanced gastric cancer
    Yang, Tingsong
    Shen, Xiaojun
    Tang, Xiaojun
    Wei, Guo
    Zhang, Hao
    Du, Chenghui
    Xue, Xuchao
    Ma, Liye
    Nie, Mingming
    Bi, Jianwei
    [J]. TUMORI, 2011, 97 (04) : 466 - 472
  • [10] Capecitabine and oxaliplatin (XELOX) as first-line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC)
    Salud, A.
    Escudero, P.
    Feliu, J.
    Lopez-Gomez, L.
    Bolanos, M.
    Galan, A.
    Yubero, A.
    Vicent, J. M.
    Losa, F.
    Gonzalez-Baron, M.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 190 - 190